“Infection and Antimicrobial Prophylaxis in Pediatric Acute Myeloid Leukemia” By Evan Liddington and “Real-World Analysis of Pseudo-Acute Kidney Injury in Breast Cancer Patients Treated with Abemaciclib” By Alexis Fanshier

Speakers: 

Alexis Fanshier, PharmD, PGY2 Oncology Pharmacy Resident, Geisinger - has nothing to disclose.
Evan Liddington, PharmD, PGY2 Oncology Pharmacy Resident, Geisinger - has nothing to disclose.

Moderator: 

Tristan Maiers, PharmD, BCOP, PGY2 Residency Program Director, Geisinger - has nothing to disclose. 
 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

  • Explain the infection risk associated with AML and chemotherapy treatment regimens
  • Review common antimicrobial practices and infection incidence among pediatric AML patients
  • Analyze improvements in clinical practice surrounding antimicrobial use in pediatric AML
  • Explain the pathophysiology of abemaciclib-associated pseudo-AKI.
  • Analyze real-world clinical outcomes and therapy modifications associated with serum creatinine elevations.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Tristan Maiers, PharmD, BCOP, Rajiv Panikkar, MD, Michele Long, BSN, Jaime Weeder, NP, Erika Bross, PA, and Erika Bross, PA have no identified disclosures. 
 
CE Committee Member/Content Reviewers have nothing to disclose. 
 
Any/All relevant financial relationships have been mitigated. 
 

Content Disclosure: 

This presentation/content is HIPAA compliant. 
 

Commercial Support for this Session:

None
Session date: 
05/15/2026 - 2:00pm to 3:00pm EDT
Location: 
Geisinger Medical Center and Virtual via Teams
100 North Academy Avenue
Knapper Hem/Onc Conference Room and Virtual via Teams
Danville, PA 17822
United States
See map: Google Maps
Add to calendar: 
  • 1.00 AAPA Category I CME
  • 1.00 ACPE
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation Credit
Please login or register to take this course.